SCHEMBL3046349

SCHEMBL3046349

NC(=O)[C@H]1CN(c2cc(F)c3nc(N4CCS(=O)(=O)CC4)sc3c2)C(=O)O1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOA P21397 3/20 0.51
MAPT P10636 6/20 0.41
F10 P00742 2/20 0.41
SMN1; SMN2 Q16637 6/20 0.40
RAB9A P51151 4/20 0.40
NPC1 O15118 2/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.34
TP53 P04637 1/20 0.33
NAAA Q02083 1/20 0.33
USP2 O75604 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TSHR P16473 1/20 0.32
CASP3 P42574 1/20 0.32
SENP8 Q96LD8 1/20 0.32
SENP7 Q9BQF6 1/20 0.32
SENP6 Q9GZR1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3041760 0.89 F10 (0.41) MAOAMAPTF10SMN1; SMN2RAB9A
SCHEMBL3043493 0.89 MAOA (0.53) MAOAMAPTF10SMN1; SMN2RAB9A
SCHEMBL3041344 0.89 MAOA (0.66) MAOAMAPTF10SMN1; SMN2RAB9A
SCHEMBL3039188 0.89 MAOA (0.53) MAOAMAPTF10SMN1; SMN2RAB9A
SCHEMBL3035349 0.82 MAOA (0.55) MAOAMAPTF10SMN1; SMN2RAB9A
SCHEMBL3033036 0.81 MAOA (0.48) MAOAMAPTF10SMN1; SMN2RAB9A
SCHEMBL13515435 0.81 MAOA (0.75) MAOAF10LMNA
SCHEMBL3038838 0.78 MAOA (0.43) MAOAMAPTF10SMN1; SMN2RAB9A
SCHEMBL3045247 0.78 MAOA (0.41) MAOAMAPTF10SMN1; SMN2RAB9A
SCHEMBL4243067 0.77 MAOA (0.69) MAOAF10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-07-29 US claimed
US-7645781-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER INC (US) 2010-01-12 US disclosed
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives THOMAS RICHARD C 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 MAOA 957/4885MAPT 4491/4885F10 4479/4885
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 MAOA 957/4885MAPT 4491/4885F10 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.